The U.S. Food and Drug Administration named the first nine recipients of its Commissioner’s National Priority Review Voucher (CNPV) pilot, a program that can compress review timelines to as little as one to two months for products addressing national priorities. The selected companies span rare disease, oncology and other high‑need areas, potentially accelerating decisions and market access for qualifying submissions. Disc Medicine and other named firms stand to benefit from dramatically shortened review clocks; Disc’s NDA for bitopertin in erythropoietic protoporphyria (EPP) was cited as a candidate for near‑term approval given the CNPV designation. Agency officials framed the pilot as a targeted way to incentivize development in areas of public health importance. Industry observers warned the program will reconfigure prioritization dynamics at the FDA and could influence corporate filing strategies and investor expectations around near‑term regulatory outcomes.